Integrin inhibitor and uses thereof
AssigneePliant Therapeutics, Inc.
InventorsJacob Cha, Katerina Leftheris, Qi Gao, Jian Wang, Dalian Zhao
Life of this patent
Estimating the term…
Abstract
Provided herein are integrin inhibitors, compositions thereof, and methods of their uses. Crystalline forms of salts of the inhibitors are also described, along with methods of preparing the crystalline forms. X-ray powder diffraction data, thermogravimetric analysis, and differential scanning calorimetry data are provided for the crystalline forms. The integrin inhibitors are useful for treatment of, inter alia, fibrotic diseases.
Claims26
A crystalline form of a phosphate salt of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid, wherein the crystalline form is characterized as having an XRPD pattern comprising a peak at an angle 2-theta of 4.31±0.2 degrees.
A crystalline form of a fumarate salt of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid, wherein the crystalline form is characterized as having an XRPD pattern comprising a peak at angle 2-theta of 8.47±0.2 degrees.
A crystalline form of a 1,5-naphthalenedisulfonate salt of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid, wherein the crystalline form is characterized as having an XRPD pattern comprising a peak at an angle 2-theta of 12.58±0.2 degrees.
Dependencies are inferred from the claim text.